Novavax has beaten earnings estimates in 3 of the last 4 quarters with an average surprise exceeding 270%, and analysts project 53% upside to their target, but a 28% short interest and weak quality metrics leave the stock in high-risk territory.
Thesis pillars
- Quality And Moat Deficit→Stable
- Earnings Beat Streak And Upside↓Deteriorating
- Analyst Upside Vs High Short Interest→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026
Novavax, Inc. (NVAX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.32: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum.
Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the FDA-approved Nuvaxovid™ (COVID-19 Vaccine) commercialized by Sanofi beginning in 2025. Revenue comes from Sanofi milestone payments and royalties, APA... Read more
Sell if holding. Engine safety override at $10.32: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.40, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: speculative.
About Novavax, Inc.
About Novavax, Inc.
Novavax's FDA-approved COVID-19 Vaccine, Nuvaxovid, received BLA approval in May 2025 for adults 65 and older and high-risk individuals aged 12 through 64, then was transferred to Sanofi under the Sanofi CLA in November 2025. The company reported net income of $440.3 million for fiscal year 2025, driven largely by $575.7 million in deferred revenue recognized upon termination of the Canada APA in March 2025. Matrix-M adjuvant licensing to Sanofi and, since January 2026, Pfizer, defines the forward revenue strategy.
Novavax earns revenue through product deliveries under remaining APA obligations — including $133.9 million under the Australia APA and $225.0 million under Gavi — alongside milestones and royalties from the Sanofi CLA, where the remaining COVID-19 milestone is $75 million contingent on completing technology transfer of the manufacturing process. In January 2026, a license agreement with Pfizer provided a $30 million upfront payment plus up to $500 million in development and sales milestones with tiered mid-single-digit royalties. Serum Institute of India manufactures the R21/Matrix-M adjuvant malaria vaccine, which reached 24 countries by February 2026 and pays Novavax royalties in the single- to low-double-digit range for 15 years per country. Takeda holds an exclusive Japan license for the COVID-19 Vaccine under the Amended Takeda CLA, which generated $40.9 million of license revenue in 2025.
Show full overview
The Sanofi CLA structures Novavax's primary commercial revenue pathway: up to $350 million in COVID-19 milestones (with $75 million remaining, contingent on technology transfer completion) plus up to $350 million in CIC development and launch milestones. If Sanofi fails to advance licensed products or technology transfer is delayed, milestone payments could be forfeited and the agreement may be terminated. The Australia APA also carries up to $92.5 million in deferred revenue refundable if delivery or regulatory approval deadlines are missed; Novavax withdrew its Australian vaccine application in the third quarter of 2025 after TGA recommendations, and discussions with Australia are ongoing.
See also: Healthcare · Biotechnology
From Novavax, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Novavax, Inc.
Latest news
- NEWS Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 — fiscal.ai Oct 29, 2026
- NEWS Cantor Fitzgerald Maintains Buy Rating on Novavax — fiscal.ai Oct 28, 2026 positive
- NEWS Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push — benzinga Oct 19, 2026 neutral
- NEWS Shah Capital Cuts Novavax Stake To 6.39%, Sells 2.87M Shares At Average Price Of $11.35/Share, Restructures Holdings Int — benzinga Oct 16, 2026 neutral
- NEWS Shah Capital Filed To Voluntarily Withdraw Its Registration As An Investment Adviser With SEC, Effective Oct. 16; Shah C — benzinga Oct 16, 2026 neutral
Generated 2026-10-29T13:34:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMcounterpartySanofi10-K Item 1: 'In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™).'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Unprofitable operations — net margin -59.9%. Quality floor flags this regardless of sector context.static
Volatile — 9.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.32: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.60. Score 5.1/10, moderate confidence.
Analyst target: $12.37 (+19.9% upside). Prior stop was $9.60. Stop-loss: $9.60.
Quality below floor (2.3 < 4.0).
Novavax, Inc. trades at a P/E of N/A (forward -63.0). TrendMatrix value score: 7.5/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the...
Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the FDA-approved Nuvaxovid™ (COVID-19 Vaccine) commercialized by Sanofi beginning in 2025. Revenue comes from Sanofi milestone payments and royalties, APA deliveries, and Matrix-M adjuvant licensing including a $30 million upfront from Pfizer in January 2026.